General Psychiatry - Articles - Page 128

“Risk Syndrome for First Psychosis”: A Valid Diagnosis in Psychiatry?

December 1, 2009

Daniel Carlat, MD

One of the most controversial topics for the DSM-V committee is whether to include a new diagnosis called Risk Syndrome for First Psychosis. Patients with schizophrenia commonly report a history of prodromal symptoms before developing the full-blown disorder...

Robust support for mood stabilizers in borderline personality disorder

December 1, 2009

Section editor, Glen Spielmans, PhD

While we typically pick and choose among various drug classes to treat patients with borderline personality disorder (BPD), we have a hard time basing our choices on the evidence.

Is Intuniv (guanfacine XR) effective for ADHD?

December 1, 2009

Section editor, Glen Spielmans, PhD

Guanfacine, an alpha-2 agonist, is sometimes prescribed off-label for ADHD and has now received official FDA approval in a new, extended-release formulation. Shire will soon market the drug under the brand name Intuniv. So how well does it work?

Adjunctive telephone therapy is cost-effective when added to antidepressants

December 1, 2009

Section editor, Glen Spielmans, PhD

In order to test whether phone therapy is helpful as an adjunct to antidepressant medication, researchers enrolled 600 depressed outpatients in a randomized trial.

Topics in the Treatment of Schizophrenia

December 1, 2009

Dost Ongur, PhD, MD

TCPR-December-2009-Tx-Schizophrenia_DostOngurMD_headshot.png

Dost Ongur, MD. Clinical Director, Schizophrenia and Bipolar Disorder Program, McLean Hospital
Assistant Professor of Psychiatry , Harvard Medical School
Dr. Ongur has disclosed that he has received free study medication (Riluzole) from Sanofi Aventis for a study on bipolar depres-
sion. Dr. Carlat has found that there is no evidence of commercial bias in this educational activity.

Dr. Ongur, over the past few decades, the dominant theory of schizophrenia has been the dopamine hypothesis, but that has been changing lately. Can give us a quick review of the original hypothesis and then go on to some of the alternative neurochemical theories?

Learning Objectives, Treating Schizophrenia, TCPR, December 2009

December 1, 2009

After reading these articles, you should be able to…

Off-Label Treatments for Anxiety Disorders

November 1, 2009

Daniel Carlat, MD

Your patient has anxiety, and you’ve tried the usual medications. You’ve rotated through your favorite SSRIs and SNRIs, tried some of the benzodiazepines, and even given buspirone a whirl to no avail. It’s time to go off-label.

Panic Disorder, Social Phobia, and OCD: Is Cognitive Behavioral Therapy Still the Best?

November 1, 2009

Glen Spielmans, PhD

Most treatment guidelines recommend cognitive behavioral therapy as first-line psychotherapy for anxiety disorders. In this article, Dr. Glen Spielmans will give you a brief primer of CBT techniques for panic disorder, social phobia, and obsessive-compulsive disorder, as well as review whether, for these conditions, CBT is indeed superior to other forms of therapy.

Abilify for Depression and Bipolar Disorder: A Meta-Analysis

November 1, 2009

Section editor, Glen Spielmans, PhD

Abilify (aripiprazole), which has long been FDA-approved for both schizophrenia and manic episodes of bipolar disorder, was recently approved for augmentation of antidepressants in patients with treatment-resistant depression.

Can an EEG Predict Antidepressant Response?

November 1, 2009

Section editor, Glen Spielmans, PhD

Clinical trials show which treatments work for “the average patient,” but we have little ability to predict which treatment will work best for any individual patient. QEEG (quantitative EEG) is a method in which a computer program reads EEG tracings and scores them along certain dimensions.

General Psychiatry
RSS

“Risk Syndrome for First Psychosis”: A Valid Diagnosis in Psychiatry?

Robust support for mood stabilizers in borderline personality disorder

Is Intuniv (guanfacine XR) effective for ADHD?

Adjunctive telephone therapy is cost-effective when added to antidepressants

Topics in the Treatment of Schizophrenia

Learning Objectives, Treating Schizophrenia, TCPR, December 2009

Off-Label Treatments for Anxiety Disorders

Panic Disorder, Social Phobia, and OCD: Is Cognitive Behavioral Therapy Still the Best?

Abilify for Depression and Bipolar Disorder: A Meta-Analysis

Can an EEG Predict Antidepressant Response?

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Psychopharm Secrets: Starting Meds

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry RSS

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry
RSS